Biogen Pharmachem Industries Board of Directors
Get the latest insights into the leadership at Biogen Pharmachem Industries. Learn about the experienced professionals guiding the company's strategy and governance.
| Name | Position |
|---|---|
| Mr. Niraj Vaghela | WholeTime Director & CFO |
| Mr. Chandrakant Govindbhai Parmar | Director |
| Mr. Chhayaben Parmar | Director |
| Mr. Narendrakumar Vaniya | Director |
| Mr. Komalben Chauhan | Director |
| Mr. Harshadkumar Rathod | Director |
Biogen Pharmachem Industries Share price
BIOGEN
0.9
0.01 (1.12%)Last updated on 29 Aug, 2025 | 15:29 IST
BUYSELL
Today's High
0.90
Today's Low
0.88
52 Week Low
0.75
52 Week High
1.45
The current prices are delayed, login to your account for live prices
LoginBiogen Pharmachem Industries FAQs
The board at Biogen Pharmachem Industries consists of experienced professionals, including Mr. Niraj Vaghela , Mr. Chandrakant Govindbhai Parmar , and others, overseeing the company’s strategic and corporate governance.
Directors at Biogen Pharmachem Industries are typically nominated by the Nomination and Remuneration Committee and approved by shareholders, adhering to regulatory and governance standards. While this is the standard procedure, the exact process may differ depending on the company’s internal policies and governance framework.
As of the latest update, Mr. Niraj Vaghela is the current chairman at Biogen Pharmachem Industries.
Executive directors at Biogen Pharmachem Industries are involved in day-to-day operations, while non-executive directors, including independents, provide oversight and strategic input. While this distinction is generally followed, the specific responsibilities of executive and non-executive directors may vary based on the company’s organisational structure and governance practices.
Yes, Biogen Pharmachem Industries adheres to all applicable SEBI and Companies Act provisions related to board structure, diversity, and independence.
At Biogen Pharmachem Industries, board members usually serve fixed terms as outlined in the company’s charter or governance policy, commonly ranging between three to five years, with the possibility of renewal based on performance, shareholder approval, and regulatory norms.